Targovax ASA: PDMR notices
Circio Holding ASA (CRNA) · publisert 2021-10-27 07:34 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Erik Digman Wiklund | CEO | other | 250 000 | 0 NOK | 2021-10-20 | NO0010689326 | – | rules · til gjennomgang |
| Ola Melin | Head of Manufacturing | other | 250 000 | 0 NOK | 2021-10-01 | NO0010689326 | – | rules · til gjennomgang |
| Lone Ottesen | Chief Development Officer | other | 350 000 | 0 NOK | 2021-07-01 | NO0010689326 | – | rules · til gjennomgang |
| Eva-Lotta Allan | Board member | other | 11 361 | 8,8 NOK | 2021-03-17 | NO0010689326 | – | rules |
| Robert Burns | Board member | other | 34 083 | 8,8 NOK | 2021-03-17 | NO0010689326 | – | rules |
| Damian Marron | Board member | other | 19 503 | 8,8 NOK | 2021-03-17 | NO0010689326 | – | rules |
| Diane Mellett | Board member | other | 22 722 | 8,8 NOK | 2021-03-17 | NO0010689326 | – | rules |
| Sonia Quaratino | Board member | other | 22 722 | 8,8 NOK | 2021-03-17 | NO0010689326 | – | rules |
| Bente-Lill Romøren | Board member | other | 11 361 | 8,8 NOK | 2021-03-17 | NO0010689326 | – | rules |
Vedlegg
- 21_10_2021_Notification_by_Primary_Insiders_Wiklund.pdf (tekst hentet ut)
- 03_10_2021_Notification_by_Primary_Insiders_Melin.pdf (tekst hentet ut)
- 02_07_2021_Notification_by_Primary_Insiders_Ottesen.pdf (tekst hentet ut)
- 18_03_2021_Notifications_by_Primary_Insiders_Board.pdf (tekst hentet ut)
Meldingstekst
Oslo, 27 October 2021: Reference is made to the mandatory notifications of trade
by primary insiders sent by Targovax ASA ("Targovax" or the "Company") on 21
October 2021, 3 October 2021, 2 July 2021 and 18 March 2021.
Please see the attached notifications of trading pertaining to the
abovementioned mandatory notifications of trade by primary insiders.
21.10.2021 Notification by Primary
Insiders_Wiklund.pdf (https://mb.cision.com/Public/17093/3441287/98923df11f009dcd
.pdf)
03.10.2021 Notification by Primary
Insiders_Melin.pdf (https://mb.cision.com/Public/17093/3441287/b30fc661b005a89c.p
df)
02.07.2021 Notification by Primary
Insiders_Ottesen.pdf (https://mb.cision.com/Public/17093/3441287/99f23eb239ce776d
.pdf)
18.03.2021 Notifications by Primary
Insiders_Board.pdf (https://mb.cision.com/Public/17093/3441287/9d161cd12d904f29.p
df)
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 906 56 525
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company's product candidates are designed to harness the
patient's own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.
Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.